Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Red Script Ventures : Another addition to Johnson & Johnson's early stage R&D tool-box

This article was originally published in Start Up

Executive Summary

Red Script is a business accelerator whose purpose is to make early stage investments--either seed or Series A-- in companies developing riskier, but potentially transformative-types of science, such as regenerative medicine or neurostimulation.

You may also be interested in...



Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Boehringer Ingelheim Joins The Corporate Venture Party

In late March, Boehringer Ingelheim GMBH formally unveiled its $134 million corporate venture fund, a strategically-focused effort that will invest in areas believed to be important to the privately-held German pharma's future growth, including RNA silencing, stem cells, and next generation vaccine, protein, and antibody technologies.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel